Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FS102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| FS102 | EXPERIMENTAL | Dose escalation of either weekly or Q3W of FS102 |
| Name | Type | Description |
|---|---|---|
| FS102 | DRUG | Experimental |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: 1. Signed written informed consent obtained prior to performing any study procedure, including screening procedures. 2. Men and women ≥ 18-years-old on the day of signing infor...
FS102 is an investigational small molecule developed by Bristol-Myers Squibb for solid tumors that overexpress HER2, also called HER2 positive tumors. It was evaluated in a single Phase 1 clinical trial and is not an approved therapy.
FS102 was studied for the treatment of solid tumors that overexpress HER2, meaning HER2 positive cancers. The Phase 1 trial enrolled adults with these HER2 positive solid tumors. FS102 is investigational and has not been approved for any use.
FS102 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of FS102 in HER2 positive solid tumors.
FS102 is in Phase 1 development. It has completed one Phase 1 trial, and no later-stage trials have been recorded. FS102 is investigational and is not FDA approved.
FS102 was studied in one Phase 1 trial, NCT02286219, titled a Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors. The trial enrolled 30 participants across the United States and Canada and is completed.
The FS102 Phase 1 trial, NCT02286219, was an uncontrolled, non-randomized, open-label study, so participants were not assigned by chance and neither participants nor investigators were blinded to treatment. It enrolled 30 adults aged 18 years and older with HER2 positive solid tumors.